FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management

Up | AC Home Page

Food and Drug Administration

Peripheral and Central Nervous System Drugs Advisory Committee

March 7 & 8, 2006

Briefing Information

 FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. 552). These redacted portions will appear as 'XXXX' on the screen or on the printed page.

FDA Table of Contents (PDF)

Tab 1. Draft Agenda (PDF)

Tab 2. Clinical Review, FDA (PDF)

Tab 3. Statistical review, FDA (PDF)

Tab 4. FDA Office of Drug Safety Risk Management Action Plan (RiskMAP) Review, FDA (PDF)

Tab 5. Questions to Advisory Committee (PDF)

Tab 6. New England Journal of Medicine publications of Natalizumab-related PML cases

Bibliography (PDF)

 

Tab 7. Original Approved Package Insert (dated November 2004)

(PDF)

 

Biogen Idec, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 Briefing Material (PDF)

 


Up | AC Home Page

Page last updated March 6, 2006 kkhorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management